Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
Active, not recruitingNCT05417737
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025
Study details
- Official title
- Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025. (EPOOzo)
- Conditions
- Radiation Toxicity
- Chemotherapeutic Toxicity
- Chemotherapy-induced Peripheral Neuropathy
- Delayed Wound Healing
- Chronic Pain
- Refractory Pain
- Interventions
- Other: Ozone therapy
- Sponsor
- Bernardino Clavo, MD, PhD
- Collaborators
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias; Servicio Canario de Salud; Council of Gran Canaria; Red de Investigación en Servicios de Salud en Enfermedades Crónicas; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna
- Organization
- Hospital Universitario de Gran Canaria Doctor Negrín
- Start date
- 2022-06-15
- Primary completion
- 2026-04-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Spain
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Adults \> = 18 years old. 2. Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity. 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment. 4. Patients have no contraindications for ozone treatment. 5. Patients have signed and dated the informed consent for the compassionated ozone treatment and the specific informed consent for this study Exclusion Criteria: 1. Age \< 18 years old. 2. Psychiatric illness or social situations that would limit compliance with study requirements. 3. Those who are incapable to fill in the scales used to measure variables. 4. Hemodynamically or clinically unstable patients or uncontrolled severe illness. 5. Uncontrolled cancer disease requiring chemotherapy treatment. 6. Life expectancy \< 6 months 7. Contraindication or disability or to attend scheduled treatments. 8. Known allergy to ozone. 9. Pregnancy at the time of enrollment (for systemic ozone therapy). 10 Hemochromatosis (for systemic ozone therapy). 11\. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy). 12\. Patients who do not meet all the inclusion criteria
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05417737